Single CRISPR Treatment Shows Lasting Reduction in 'Bad' Cholesterol for a Full Year

A first-in-human Phase 1 clinical trial conducted by Cleveland Clinic found that a single infusion of a CRISPR-Cas9 gene-editing therapy significantly reduced LDL ('bad') cholesterol and triglycerides in patients with lipid disorders unresponsive to conventional medications. After 12 months, participants receiving the highest dose experienced a 52.5% reduction in LDL cholesterol and a 47.8% drop in triglycerides from baseline, with no serious adverse events related to the therapy reported. These findings were presented at the 2026 European Society of Cardiology annual meeting and simultaneously published in the New England Journal of Medicine.